In hepatocellular (HCC) and colon carcinomas, for example, a low FXR expression has been demonstrated and, consistently, FXR activation has resulted in a significant repression of liver and colon cancer progression, primarily mediated by FXR-dependent inhibition of β-catenin activity [13–15]. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.